 |
Video: What is a Stock Split?
|
 |
Molecular Templates is a clinical-stage company focused on the discovery and development of biologic therapeutic for cancer and other serious diseases. Co. utilizes its proprietary biologic drug platform to design and generate engineered toxin bodies (ETBs). Co. is developing ETBs for various targets, including CD20, CD38, HER2, PD-L1, CTLA-4, SLAMF-7, and CD45. CD20 is central to B cell malignancies and is clinically validated as a target for the treatment of lymphomas and autoimmune disease. CD38 has been validated as a clinical target in the treatment of various myeloma. PD-L1 is central to immune checkpoint pathways and is a target expressed in a variety of solid tumor cancers. According to our MTEM split history records, Molecular Templates has had 1 split. | |
 |

Molecular Templates (MTEM) has 1 split in our MTEM split history database. The split for MTEM took place on August 02, 2017. This was a 1 for 11 reverse split, meaning for each 11 shares of MTEM owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 90.9090909090909 share position following the split.
When a company such as Molecular Templates conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the MTEM split history from start to finish, an original position size of 1000 shares would have turned into 90.9090909090909 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Molecular Templates shares, starting with a $10,000 purchase of MTEM, presented on a split-history-adjusted basis factoring in the complete MTEM split history.

Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
03/03/2011 |
|
End date: |
03/02/2021 |
|
Start price/share: |
$23.98 |
|
End price/share: |
$11.29 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-52.92% |
|
Average Annual Total Return: |
-7.25% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$4,709.34 |
|
Years: |
10.01 |
|
|
 |
Date |
Ratio |
08/02/2017 | 1 for 11 |
|
 |